We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines.
We focus on developing drugs that stop or reverse a disease state using novel targets that we identify through a patent protected genomics platform. To maximise the potential of the proprietary technology, we provide access to our target and drug discovery platform through our services division BioFocus DPI.
Galapagos focuses its internal programs on developing new drugs in the bone and joint diseases- osteoarthritis, osteoporosis and rheumatoid arthritis. BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery to validation and drug discovery services through to delivery of pre-clinical candidates.In addition, BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets, natural and synthetic compound libraries for drug screening, chemogenomics and ADME database products to select targets and compounds, and compound management facilities for compound delivery to multiple screening centers.

May 6, 2008
Galapagos and Allergan enter drug discovery collaboration
Read more

April 2008
PharmaVentures interview with Onno van de Stolpe April 2008

April 16, 2008
Galapagos licenses clinical rheumatoid arthritis program
Read more
View webcast presentation here

April 14, 2008
Galapagos appoints Piet Wigerinck as Senior VP Development
Read more